Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(1):179–183. doi: 10.1038/sj.bjc.6690669

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

S Wang-Gohrke 1, W Weikel 2, H Risch 3, D Vesprini 4, J Abrahamson 4, C Lerman 5, A Godwin 6, R Moslehi 7, O Olipade 8, J-S Brunet 4, E Stickeler 1, D G Kieback 1,*, R Kreienberg 1, B Weber 9, S A Narod 4, I B Runnebaum 1,*
PMCID: PMC2374363  PMID: 10487631

Abstract

Two biallelic polymorphisms in introns 3 and 6 of the p53 gene were analysed for a possible risk-modifying effect for ovarian cancer. Germline DNA was genotyped from 310 German Caucasian ovarian cancer patients and 364 healthy controls. We also typed 124 affected and 276 unaffected female carriers with known deleterious BRCA1 or BRCA2 germline mutation from high-risk breast-ovarian cancer families. Genotyping was based on PCR and high-resolution gel electrophoresis. German ovarian cancer patients who carried the rare allele of the MspI restriction fragment length polymorphism (RELP) in intron 6 were found to have an overall 1.93-fold increased risk (95% confidence internal (CI) 1.27–2.91) which further increased with the age at diagnosis of 41–60 years (odds ratio (OR) 2.71, 95% CI 1.10–6.71 for 41–50 and OR 2.44, 95% CI 1.12–5.28 for 51–60). The 16 bp duplication polymorphism in intron 3 was in a strong linkage to the MspI RFLP. In BRCA1 or BRCA2 mutation carriers, no difference in allele frequency was observed for carriers affected or unaffected with ovarian cancer. Our data suggest that intronic polymorphisms of the p53 gene modify the risk for ovarian cancer patients but not in carriers with BRCA1 or BRCA2 mutations. © 1999 Cancer Research Campaign

Keywords: ovarian cancer, p53, polymorphism, BRCA1, BRCA2, genetic susceptibility

Full Text

The Full Text of this article is available as a PDF (92.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avigad S., Barel D., Blau O., Malka A., Zoldan M., Mor C., Fogel M., Cohen I. J., Stark B., Goshen Y. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene. 1997 Apr 3;14(13):1541–1545. doi: 10.1038/sj.onc.1200990. [DOI] [PubMed] [Google Scholar]
  2. Beenken S. W., Karsenty G., Raycroft L., Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res. 1991 Sep 11;19(17):4747–4752. doi: 10.1093/nar/19.17.4747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Birgander R., Själander A., Rannug A., Alexandrie A. K., Sundberg M. I., Seidegård J., Tornling G., Beckman G., Beckman L. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis. 1995 Sep;16(9):2233–2236. doi: 10.1093/carcin/16.9.2233. [DOI] [PubMed] [Google Scholar]
  4. Buller R. E., Skilling J. S., Kaliszewski S., Niemann T., Anderson B. Absence of significant germ line p53 mutations in ovarian cancer patients. Gynecol Oncol. 1995 Sep;58(3):368–374. doi: 10.1006/gyno.1995.1244. [DOI] [PubMed] [Google Scholar]
  5. Hahn M., Serth J., Fislage R., Wolfes H., Allhoff E., Jonas V., Pingoud A. Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin Chem. 1993 Mar;39(3):549–550. [PubMed] [Google Scholar]
  6. Hillebrandt S., Streffer C., Demidchik E. P., Biko J., Reiners C. Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus. Mutat Res. 1997 Nov 28;381(2):201–207. doi: 10.1016/s0027-5107(97)00169-3. [DOI] [PubMed] [Google Scholar]
  7. Hinds P. W., Finlay C. A., Quartin R. S., Baker S. J., Fearon E. R., Vogelstein B., Levine A. J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1990 Dec;1(12):571–580. [PubMed] [Google Scholar]
  8. Ito T., Seyama T., Hayashi T., Mizuno T., Iwamoto K. S., Tsuyama N., Dohi K., Nakamura N., Akiyama M. HaeIII polymorphism in intron 1 of the human p53 gene. Hum Genet. 1994 Feb;93(2):222–222. doi: 10.1007/BF00210619. [DOI] [PubMed] [Google Scholar]
  9. Lancaster J. M., Brownlee H. A., Wiseman R. W., Taylor J. p53 polymorphism in ovarian and bladder cancer. Lancet. 1995 Jul 15;346(8968):182–182. doi: 10.1016/s0140-6736(95)91239-8. [DOI] [PubMed] [Google Scholar]
  10. Lazar V., Hazard F., Bertin F., Janin N., Bellet D., Bressac B. Simple sequence repeat polymorphism within the p53 gene. Oncogene. 1993 Jun;8(6):1703–1705. [PubMed] [Google Scholar]
  11. Lynch H. T., Smyrk T. C., Watson P., Lanspa S. J., Lynch J. F., Lynch P. M., Cavalieri R. J., Boland C. R. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 1993 May;104(5):1535–1549. doi: 10.1016/0016-5085(93)90368-m. [DOI] [PubMed] [Google Scholar]
  12. Lynch H. T., Watson P., Bewtra C., Conway T. A., Hippee C. R., Kaur P., Lynch J. F., Ponder B. A. Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer. 1991 Mar 1;67(5):1460–1466. doi: 10.1002/1097-0142(19910301)67:5<1460::aid-cncr2820670534>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  13. Mavridou D., Gornall R., Campbell I. G., Eccles D. M. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer. 1998 Feb;77(4):676–677. doi: 10.1038/bjc.1998.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Peller S., Kopilova Y., Slutzki S., Halevy A., Kvitko K., Rotter V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol. 1995 Dec;14(12):983–990. doi: 10.1089/dna.1995.14.983. [DOI] [PubMed] [Google Scholar]
  15. Phelan C. M., Rebbeck T. R., Weber B. L., Devilee P., Ruttledge M. H., Lynch H. T., Lenoir G. M., Stratton M. R., Easton D. F., Ponder B. A. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 1996 Mar;12(3):309–311. doi: 10.1038/ng0396-309. [DOI] [PubMed] [Google Scholar]
  16. Pleasants L. M., Hansen M. F. Identification of a polymorphism in intron 2 of the p53 gene. Hum Genet. 1994 May;93(5):607–608. doi: 10.1007/BF00202835. [DOI] [PubMed] [Google Scholar]
  17. Prosser J., Condie A. Biallelic ApaI polymorphism of the human p53 gene (TP53). Nucleic Acids Res. 1991 Sep 11;19(17):4799–4799. doi: 10.1093/nar/19.17.4799-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Runnebaum I. B., Tong X. W., König R., Zhao H., Körner K., Atkinson E. N., Kreienberg R., Kieback D. G., Hong Z [corrected to Zhao H. ]. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet. 1995 Apr 15;345(8955):994–994. doi: 10.1016/s0140-6736(95)90745-9. [DOI] [PubMed] [Google Scholar]
  19. Shamsher M., Montano X. Analysis of intron 4 of the p53 gene in human cutaneous melanoma. Gene. 1996 Oct 17;176(1-2):259–262. doi: 10.1016/0378-1119(96)00000-5. [DOI] [PubMed] [Google Scholar]
  20. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]
  21. Wang-Gohrke S., Rebbeck T. R., Besenfelder W., Kreienberg R., Runnebaum I. B. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res. 1998 May-Jun;18(3B):2095–2099. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES